Public Sector Pension investment Board decreased its holdings in Emergent Biosolutions, Inc. (NYSE:EBS) by 26.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,781 shares of the biopharmaceutical company’s stock after selling 6,500 shares during the quarter. Public Sector Pension investment Board’s holdings in Emergent Biosolutions were worth $603,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Creative Planning boosted its holdings in shares of Emergent Biosolutions by 1.2% in the second quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 55 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of Emergent Biosolutions by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 14,200 shares of the biopharmaceutical company’s stock worth $482,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Emergent Biosolutions by 0.6% in the second quarter. Arizona State Retirement System now owns 18,160 shares of the biopharmaceutical company’s stock worth $616,000 after buying an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its holdings in shares of Emergent Biosolutions by 1.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 10,720 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 180 shares during the last quarter. Finally, Eqis Capital Management Inc. boosted its holdings in shares of Emergent Biosolutions by 0.7% in the second quarter. Eqis Capital Management Inc. now owns 38,382 shares of the biopharmaceutical company’s stock worth $1,302,000 after buying an additional 271 shares during the last quarter. 85.35% of the stock is currently owned by institutional investors.

EBS has been the topic of a number of research reports. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Zacks Investment Research downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $43.00 price target (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $45.00.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/public-sector-pension-investment-board-reduces-position-in-emergent-biosolutions-inc-ebs/1617243.html.

In other news, Director Jerome M. Hauer sold 10,776 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total transaction of $386,104.08. Following the transaction, the director now owns 29,421 shares in the company, valued at approximately $1,054,154.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Fuad El-Hibri sold 25,000 shares of the stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $36.50, for a total value of $912,500.00. Following the transaction, the chairman now owns 1,630,216 shares in the company, valued at approximately $59,502,884. The disclosure for this sale can be found here. In the last 90 days, insiders sold 230,227 shares of company stock worth $8,793,970. Insiders own 16.50% of the company’s stock.

Emergent Biosolutions, Inc. (EBS) opened at 40.50 on Friday. The stock has a market cap of $1.67 billion, a P/E ratio of 25.80 and a beta of 1.26. The firm’s 50-day moving average is $37.85 and its 200 day moving average is $33.49. Emergent Biosolutions, Inc. has a one year low of $24.47 and a one year high of $41.46.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by ($0.13). Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The company had revenue of $100.77 million during the quarter, compared to analysts’ expectations of $111.57 million. During the same quarter in the prior year, the company posted ($0.05) EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, analysts anticipate that Emergent Biosolutions, Inc. will post $1.54 EPS for the current fiscal year.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.